OCUL.NASDAQOcular Therapeutix, INC

10-Q: Ocular Therapeutix Reports Q1 2025 Results, Highlights AXPAXLI Progress and DEXTENZA Performance

Sentiment:

Quarterly Report

📋All filings for Ocular Therapeutix, INC
🔒Login to Follow

Ocular Therapeutix announces its Q1 2025 financial results, focusing on the advancement of its AXPAXLI clinical trials and the commercial performance of DEXTENZA.

Worse than expectedProduct revenue decreased by 27.7% year-over-year, primarily due to changes in distributor stocking patterns and the impact of MIPS on buying patterns.

Summary

  • Ocular Therapeutix reported a net loss of $64.1 million for Q1 2025, compared to a net loss of $64.8 million for Q1 2024.
  • Product revenue decreased to $10.6 million from $14.7 million year-over-year, primarily due to changes in distributor stocking patterns and the impact of MIPS on buying patterns.
  • Research and development expenses increased significantly to $42.9 million, driven by the progression of AXPAXLI clinical trials.
  • The company is progressing with its SOL-1 and SOL-R Phase 3 clinical trials for AXPAXLI in wet AMD, with topline results for SOL-1 expected in Q1 2026.
  • Ocular Therapeutix is planning its next steps for AXPAXLI in NPDR and DME following positive feedback from the FDA.
  • The company believes its existing cash and cash equivalents of $349.7 million as of March 31, 2025, will fund operations into 2028, while observing a minimum liquidity covenant of $20 million in its credit facility.
  • The company anticipates quarterly net revenue should increase for the remainder of 2025, driven primarily by expected increases in the number of units sold.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company has a strong cash position and is progressing with clinical trials, revenue decreased, and losses persist. The future outlook is uncertain.

Positives

  • The company has a strong cash position of $349.7 million, expected to fund operations into 2028.
  • The SOL-1 trial completed randomization, and the SOL-R trial is enrolling well.
  • The FDA provided positive feedback on the design of a potential registrational clinical trial for AXPAXLI for the treatment of NPDR.
  • DEXTENZA received approval for pediatric use, expanding its label.
  • The company anticipates quarterly net revenue should increase for the remainder of 2025, driven primarily by expected increases in the number of units sold.

Negatives

  • Product revenue decreased by 27.7% year-over-year, primarily due to changes in distributor stocking patterns and the impact of MIPS on buying patterns.
  • The company reported a net loss of $64.1 million for Q1 2025.
  • Research and development expenses increased significantly, impacting profitability.

Risks

  • The company's future viability depends on generating cash flows from product sales and raising additional capital.
  • Clinical trials are subject to numerous risks and uncertainties, which could impact the costs and timing of development.
  • The company is dependent on a small number of third-party manufacturers and specialty distributor customers.
  • The company's estimates regarding future revenue and expenses may prove to be inaccurate.

Future Outlook

The company expects quarterly net revenue to increase for the remainder of 2025, driven by increased unit sales. Topline results for the SOL-1 trial are expected in Q1 2026.

Management Comments

  • The company is actively planning its next steps in the development of AXPAXLI for NPDR and DME and expects to provide further details at a later date.
  • The company believes that the decrease in net revenue is primarily attributable to the impact of our pricing strategy on distributor stocking patterns and buying patterns by ASCs, HOPDs and physicians offices, as well as the recent inclusion of DEXTENZA into the cost performance category of the Centers for Medicare & Medicaid Services Merit-based Incentive Payment System, or MIPS, for 2025.

Industry Context

Ocular Therapeutix is operating in the competitive biopharmaceutical industry, focusing on retinal diseases and other eye conditions. The company's success depends on the clinical trial outcomes of AXPAXLI and the commercial performance of DEXTENZA, as well as its ability to secure regulatory approvals and reimbursement for its products.

Comparison to Industry Standards

  • It is difficult to compare Ocular Therapeutix directly to industry standards without specific competitor data.
  • However, the company's focus on bioresorbable hydrogel-based drug delivery technology (ELUTYX) is a differentiating factor.
  • Competitors in the wet AMD space include companies developing anti-VEGF therapies, such as Regeneron (Eylea/aflibercept) and Roche/Novartis (Lucentis/ranibizumab and Vabysmo/faricimab).
  • Ocular Therapeutix is aiming for a longer dosing interval with AXPAXLI compared to existing anti-VEGF therapies, which could be a competitive advantage if clinical trials are successful.

Related Party Transactions

  • The Company has engaged Boston Image Reading Center LLC (BIRC) to provide certain clinical development-related services to the Company.
  • Jeffrey Heier, M.D., a former member of the Companys Board of Directors and the Companys current Chief Scientific Officer, and Peter Kaiser, M.D., the Companys current Chief Development Officer, are each affiliated with i2Vision, and its affiliated entities (collectively i2Vision).
  • The Company has engaged Wilmer Cutler Pickering Hale and Dorr LLP (WilmerHale) to provide certain legal services to the Company.

Stakeholder Impact

  • Shareholders: The company's financial performance and clinical trial progress will impact shareholder value.
  • Employees: The company's ability to fund operations and achieve milestones will affect job security and opportunities.
  • Customers: The company's products, such as DEXTENZA, provide treatment options for patients with eye conditions.
  • Suppliers: The company's relationships with suppliers are important for manufacturing and clinical trial activities.
  • Creditors: The company's ability to meet its debt obligations is crucial for maintaining financial stability.

Next Steps

  • Continue SOL-1 and SOL-R clinical trials for AXPAXLI in wet AMD.
  • Plan next steps for AXPAXLI in NPDR and DME.
  • Evaluate whether an end-of-Phase 2 meeting with the FDA is appropriate for determining our next steps for PAXTRAVA for the treatment of OAG or OHT.
  • Support the commercialization of DEXTENZA.

Key Dates

DateDescription
February 21, 2024Dr. Heier Employment Agreement effective, Heier Consulting Agreement terminated, Dr. Heier resigned from the Companys board of directors
February 26, 20242024 Private Placement closed
March 28, 2024The Company issued 5,769,232 shares of its common stock with a total fair value of $52,499 to the holder of the Convertible Notes in connection with the conversion of the principal amount of the Convertible Notes
June 1, 2024Nadia Waheed, M.D. M.P.H., has served as the Companys Chief Medical Officer
June 2024The Company adopted an amendment to its restated certificate of incorporation, as amended, increasing the number of the authorized shares of its common stock by 200,000,000 shares to 400,000,000 shares.
June 2024SOL-R trial initiated
July 2024First subject enrolled in the SOL-R trial
August 2024FDA agreed that the SOL-R repeat dosing wet AMD trial, with a primary endpoint at Week 56, should be appropriate as an adequate and well-controlled trial in support of a potential new drug application, or NDA, and product label for AXPAXLI for the treatment of wet AMD.
October 7, 2024Todd D.C. Anderman(Chief Legal Officer)Adoption (October 7, 2024)Durable Rule 10b5-1 trading arrangement for sell-to-cover transactions relating to all RSUs that have or may be granted
December 2024The SOL-1 trial completed the randomization of 344 subjects with a diagnosis of active macular choroidal neovascularization at screening in December 2024.
January 10, 2025We had enrolled 311 subjects across various stages of loading and randomization in the SOL-R trial.
January 14, 2025We announced that, as of January 10, 2025, we had enrolled 311 subjects across various stages of loading and randomization in the SOL-R trial.
January 2025we submitted a proposed SPA agreement modification to the FDA to add a repeat dose of AXPAXLI 450 g at Week 52 and at Week 76, in each case, after all pre-defined efficacy endpoint assessments, to generate the required safety data for subjects re-dosed with AXPAXLI through Week 104, to support repeat dosing.
February 11, 2025The Company granted 1,500,000 PSUs to its Executive Chairman, President and Chief Executive Officer under the 2021 Plan.
February 11, 2025On February 11, 2025, the Companys board of directors also approved a grant of 2,750,000 performance stock options (the Performance Option Award) to the Companys Executive Chairman, President and Chief Executive Officer under the 2021 Plan which can be earned based on the same conditions as those described above for the PSUs.
February 11, 2025Pravin U. Dugel(Executive Chairman, President and Chief Executive Officer)Adoption (February 11, 2025)Durable Rule 10b5-1 trading arrangement for sell-to-cover transactions relating to all PSUs that have or may be granted
February 2025We received an agreement letter regarding the SPA agreement modification from the FDA in February 2025.
Late March 2025the FDA provided positive written feedback on the design of a potential registrational clinical trial for AXPAXLI for the treatment of NPDR.
April 1, 2025Effective April 1, 2025, we increased the wholesale acquisition cost, or WAC, and we concurrently increased the off-invoice discount, or OID, for DEXTENZA as part of our overall pricing strategy.
April 7, 2025We received approval of the supplemental NDA for DEXTENZA on April 7, 2025.
May 1, 2025As of May 1, 2025, there were 159,299,736 shares of Common Stock, $0.0001 par value per share, outstanding.

Keywords

AXPAXLI, DEXTENZA, Ocular Therapeutix, Wet AMD, NPDR, Clinical Trials, Financial Results, Revenue, Research and Development, Ophthalmology

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.